Immuron Limited Announces Participation in the LD Micro Main Event XVI
- Record sales of Travelan
- Ongoing Phase 2 clinical trials
- None.
Presentation on Wednesday, October 4th at 11:00 PT
Melbourne, Australia--(Newsfile Corp. - September 18, 2023) - Immuron Limited (NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, announced today that it will be presenting at the 16th annual Main Event on Wednesday, October 4th at 11:00 PT at the Luxe Sunset Boulevard Hotel. Steven Lydeamore, CEO, will be giving the presentation.
"We know what this event means to our industry and how much people enjoy attending. Thanks to the leaders at our parent company, Freedom, who fully align with our vision, we continue to provide a conference that is much more than meetings and presentations-we're building the foundation for the coming decades as the one event in small-cap that no one can afford to miss. I am honored to host our close friends and allies for our "Sweet Sixteen" installment of the Main Event," stated Chris Lahiji, Founder of LD Micro.
Immuron recently reported: record sales of Travelan, for Digestive Tract support, wherever you are; and presentation of research at the Military Health System Research Symposium. This presentation will provide an update on Phase 2 clinical trials being conducted in collaboration with the Department of Defense.
Event: LD Micro Main Event XV
Date: Wednesday, October 4th
Time: 11:00 PT
Register to watch the virtual presentation here.
Summary of LD Micro Main Event XVI
The 2023 LD Micro Main Event XVI will run from October 3rd to the 5th at the Luxe Sunset Boulevard Hotel in Los Angeles.
Presentations will run from 8:00 AM PT - 5:00 PM PT on the 3rd and 4th, with a half day on Thursday the 5th.
This three-day event will feature around 200 companies, presenting in half-hour increments, and attending private meetings with investors.
About Immuron Limited
Immuron Limited is commercializing and developing a novel class of specifically targeted polyclonal antibodies which are delivered within the gastrointestinal tract and do not cross into the bloodstream. Products in clinical development have the potential to transform standard of care for moderate to severe Campylobacteriosis, Clostridioides difficile infections, Enterotoxigenic Escherichia coli (ETEC) infections and Traveler’s Diarrhea. Immuron markets Travelan® in Australia, Canada and the U.S. In Australia, Travelan® is indicated to reduce the risk of travelers’ diarrhea and to reduce the risk of minor gastro-intestinal disorders. In Canada, Travelan® is indicated to reduce the risk of travelers’ diarrhea. In the U.S, Travelan® is a dietary supplement for digestive tract protection.
About LD Micro
LD Micro, a wholly owned subsidiary of Freedom US Markets, was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. Through the LD Micro Index and annual investor conferences, LD has served as an invaluable asset to all those interested in discovering the next generation of great companies. For more information on LD Micro, visit www.ldmicro.com.
To present or register, please contact registration@ldmicro.com.
To learn more about Freedom US Markets, visit www.freedomusmkts.com.
For further information on Immuron Limited:
Immuron Limited
Steven Lydeamore
0388924854
steve@immuron.com
https://www.immuron.com.au/
